Cue Biopharma Inc CUE.OQ CUE.O is expected to show a fall in quarterly revenue when it reports results on March 26 (estimated) for the period ending December 31 2024
The Boston Massachusetts-based company is expected to report a 6.6% decrease in revenue to $1.701 million from $1.82 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cue Biopharma Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cue Biopharma Inc is $4.00, above its last closing price of $0.98.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.20 | -0.19 | -0.17 | Beat | 11.7 |
Jun. 30 2024 | -0.28 | -0.28 | -0.20 | Beat | 29.6 |
Mar. 31 2024 | -0.28 | -0.28 | -0.25 | Beat | 11.3 |
Dec. 31 2023 | -0.28 | -0.28 | -0.29 | Missed | -4.3 |
Sep. 30 2023 | -0.30 | -0.34 | -0.24 | Beat | 29.9 |
Jun. 30 2023 | -0.30 | -0.30 | -0.29 | Beat | 4.9 |
Mar. 31 2023 | -0.32 | -0.29 | -0.29 | Met | 0 |
Dec. 31 2022 | -0.29 | -0.31 | -0.38 | Missed | -22.6 |
This summary was machine generated March 24 at 20:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments